Data asset leverage Verana Health holds exclusive access to large real-world data sources in oncology, ophthalmology, neurology, and urology, presenting a strong opportunity to upsell data access, advanced analytics, and real-world evidence generation services to biopharma and contract research organizations seeking regulatory-grade datasets.

RWD product expansion recent updates to RWD bladder cancer database, expanded ovarian cancer dataset, and Imaging Consortium indicate a momentum in expanding curated datasets and imaging data; sales motions can target researchers and sponsors needing broader, high-quality RWD and imaging insights.

End-to-end trial support New functionality in Site Explorer and Verana Trial Connect provides end-to-end site selection and patient enrollment capabilities, creating a direct cross-sell path to CROs and sponsors seeking streamlined trial operations powered by real-world data.

AI assisted data submission Introduction of AI agents like Agent Claire to facilitate MIPS data submission signals an opportunity to offer clinician-focused workflow automation tools, compliance assistance, and ongoing data capture enhancements as add-on solutions.

Strategic partnerships Recent Guardant Health collaboration to combine clinicogenomic data with Verana’s curated EHR datasets expands the potential for co-developed therapies and joint offerings, suggesting multiple co-sell opportunities with biopharma and diagnostics partners.